Levofloxacin Eberth (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By inhibiting these targets, the drug prevents bacterial cells from multiplying, leading to a bactericidal effect against a wide range of Gram‑positive and Gram‑negative organisms.

The specific dose and duration of Levofloxacin Eberth are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local antimicrobial guidelines. Healthcare professionals should follow the approved prescribing information for dosing details.

Safety data for levofloxacin in pregnancy and lactation are limited. It should be used only when the potential benefit justifies the potential risk to the fetus or infant. Clinicians should discuss possible risks and alternatives with the patient before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levofloxacin offers a broad spectrum of activity with once‑daily dosing for many indications, and it has a favorable pharmacokinetic profile compared with some older fluoroquinolones. However, all fluoroquinolones share similar safety considerations, such as tendon toxicity and QT prolongation, so choice should be guided by susceptibility data and patient factors.

Levofloxacin Eberth should be stored at room temperature, below 25 °C, in its original packaging. The container should be kept away from moisture and direct sunlight to maintain product stability.

Levofloxacin Eberth is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of qualified healthcare personnel. The infusion rate and dilution are determined by the prescribing clinician according to standard IV administration guidelines.

Serious risks include tendon rupture or tendinitis, QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and central nervous system effects like seizures. Patients should be monitored closely for these events, especially if they have pre‑existing risk factors.

Levofloxacin Eberth should be avoided in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, and individuals with significant QT prolongation or uncontrolled cardiac arrhythmias. Caution is also advised for patients with severe renal or hepatic impairment.